Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.

NCT06195683 ↗

Phase 2 Unknown 23 enrolled Zhejiang Cancer Hospital

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to observe the efficacy and safety of Serplulimab monotherapy as a neoadjuvant treatment for TPS ≥ 50% non-small cell lung cancer (NSCLC).

Timeline

Start: 2023-12-01
Primary completion: 2024-12-31
Completion: 2025-06-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Serplulimab	Monoclonal antibody	4.5 mg/kg	—

Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.

Summary

Timeline

Drugs

Indications